Institutional
Davern Capital Partners, LP
CIK 0002003147
$364.5M
Reported AUM
17
Positions
Q1 2026
Period
2026-05-14
Filed
The Brief · Davern Capital Partners, LP · Q1 2026
AI · grounded in 13F
Davern Capital Partners, LP established a new position in INSM valued at $29.85M. The fund also initiated new stakes in GENB for $7.4M and PRCT for $6.53M, while increasing its holdings in LLY by 228.39%. On the sell side, the fund closed its position in CGON, resulting in a $6.73M reduction.
Portfolio · Q1 2026
Top holdings
| # | Stock | Issuer | Price | Day % | 1Y Gr. | 5Y Gr. | Value | % of book | Δ shares (QoQ) | Status |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PFE | PFIZER INC | $25.15 | -0.40% | 15.03% | -28.59% | $44.8M | 12.28% | — | HELD |
| 2 | REGN | REGENERON PHARMACEUTICALS | $695.42 | 0.03% | 25.16% | 4.16% | $34.6M | 9.50% | — | HELD |
| 3 | INSM | INSMED INC | $103.12 | -0.97% | -3.85% | 272.72% | $29.9M | 8.19% | — | HELD |
| 4 | IONS | IONIS PHARMACEUTICALS INC | $54.04 | -2.28% | 28.51% | 39.08% | $29.1M | 7.97% | — | HELD |
| 5 | NTRA | NATERA INC | $253.82 | 0.63% | 88.60% | 114.32% | $28.8M | 7.90% | — | HELD |
| 6 | BNTX | BIONTECH SE | $92.95 | 0.54% | -12.98% | -71.25% | $27.1M | 7.44% | — | HELD |
| 7 | ARGX | ARGENX SE | $882.56 | 1.18% | 30.98% | 166.62% | $25.6M | 7.02% | — | HELD |
| 8 | LLY | ELI LILLY & CO | $1210.02 | -0.87% | 61.25% | 393.83% | $25.1M | 6.88% | — | HELD |
| 9 | RPRX | ROYALTY PHARMA PLC | $59.18 | -1.32% | 65.07% | 73.69% | $24.9M | 6.84% | — | HELD |
| 10 | ROIV | ROIVANT SCIENCES LTD | $32.87 | -2.87% | 196.20% | 236.68% | $24.2M | 6.64% | — | HELD |
| 11 | LEGN | LEGEND BIOTECH CORP | $18.85 | -1.00% | -50.93% | -50.27% | $23.8M | 6.52% | — | HELD |
| 12 | MLYS | MINERALYS THERAPEUTICS INC | $26.35 | -2.23% | 94.44% | 69.67% | $12.1M | 3.32% | — | HELD |
| 13 | ABVX | ABIVAX SA | $118.84 | -4.34% | 72.67% | 1123.94% | $8.7M | 2.39% | — | HELD |
| 14 | GENB | GENERATE BIOMEDICINES INC | $13.08 | -0.46% | 3.87% | 5.12% | $7.4M | 2.03% | — | HELD |
| 15 | PRCT | PROCEPT BIOROBOTICS CORP | $17.88 | -1.11% | -63.81% | -57.69% | $6.5M | 1.79% | — | HELD |
| 16 | GPCR | STRUCTURE THERAPEUTICS INC | $47.35 | -1.13% | 172.26% | 101.30% | $6.1M | 1.67% | — | HELD |
| 17 | VRDN | VIRIDIAN THERAPEUTICS INC | $19.88 | 1.90% | 12.06% | 45.81% | $5.9M | 1.62% | — | HELD |
Source: SEC EDGAR · accession 0000905148-26-002267. 13F discloses long positions only — shorts, foreign equities, and options are excluded.